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ABSTRACT
OBJECTIVES: Internalizing the public stigma in patients with schizophrenia leads to self-
stigmatization associated with a number of negative consequences such as depression, low
self-esteem, hopelessness, impairment of social adaptation, unemployment, and treatment
non-adherence. No instruments have been developed to assess the self-stigmatization for
patients with schizophrenia living in Turkey. The purpose of this study was to develop a
culturally-sensitive and easy-to-use instrument to measure self-stigma of the patients with
schizophrenia and schizoaffective disorder.
METHODS: After examining the existing stigma and self-stigma scales for people with mental
illnesses, a 19-item self-stigma inventory was formed. Focus group interviews were conducted
with patients with schizophrenia and the items were reviewed and rephrased into more
comprehensible statements for the patients. The pilot study was conducted with a sample of
15 patients with schizophrenia, and the inventory was given its final form, self-stigma
inventory for patients (SSI-P). Outpatients with schizophrenia and schizoaffective disorder
were given sociodemographic form, SSI-P, Beck Depression Inventory (BDI), Internalized
Stigma of Mental Illness (ISMI), Rosenberg Self-Esteem Scale (RSES), Beck Hopelessness Scale
(BHS), Positive and Negative Syndrome Scale (PANSS), Clinical Global Impression-Severity
(CGI-S), and Global Assessment of Functioning (GAF). For reliability analyses; internal
consistency, item-total correlation, and test-retest reliability were assessed. Validity analyses
were conducted with Explanatory Factor Analysis and convergent validity.
RESULTS: The sample of the study was 162 patients with schizophrenia and schizoaffective
disorder of which 77% were males, 70% were single, mean age was 37, and level of
education was 10 years. Cronbach’s alpha coefficient of the scale was 0.93 ranging among
the subscales between 0.60 and 0.91. Kaiser-Meyer-Olkin value was 0.91, and the Barlett test
was significant (p < 0.001) for explanatory factor analysis and three factors were found
(perceived devaluation, internalized stereotypes and social withdrawal, concealment of the
illness) that can explain 63.5% of the total variance. Two items were removed because of
their low factor value, and the final form consisted of 17 items. SSI-P was highly correlated
with commonly-used stigma scale ISMI (r = 0.73), and moderately correlated with BDI (r =
0.53), BHS (r = 0.40), and RSES (r =−0.59). It also showed low correlation with PANSS negative
score (r = 0.19). The test-retest reliability coefficient of the scale was 0.83.
CONCLUSION: SSI-P is a reliable and valid instrument for assessing the self-stigmatization of
patients with schizophrenia and schizoaffective disorder. The scale is an easy-to-comprehend,
user-friendly, and culturally-sensitive tool with its 17 items.
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Stigma is generally defined as possession of some nega-
tive attributes causing the individual to be labelled as a
member of a discredited social category which results
in loss of social status and experience of discrimination
[1]. People from diverse social groups or ethnic back-
ground struggle with stigmatization in everyday life
and one of the most stigmatized group is people with
mental illnesses [2]. Patients with mental disorders
have sometimes been labelled as “nuts”, “insane”,
“crazy”, “psycho”, etc. in public view, and they are chal-
lenged by the heavy burden of these negative labels [3].
Mental illness stigma is especially destructive for
people with severe mental illness (SMI) since they
need to cope with both the symptoms of the disease
and also the discrimination and prejudice rooted
against them in the community [4].
Stigmatization of people with SMI (i.e. schizo-
phrenia, schizoaffective disorder, bipolar disorder,
etc.) has several adverse outcomes for the patients
[5,6]. Researchers indicate that social stigma restricts
the patient in terms of finding a job, living indepen-
dently, and establishing interpersonal relationships
[7]. Because of discrimination, negative and low expec-
tations, employers do not want to hire a person with a
past or current diagnosis of SMI, landlords are
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reluctant to rent their apartments out to a patient, and
people, in general, are less likely to be engaged or inter-
act with a mentally ill patient [8]. Consequently,
patients feel excluded from society, become depressed
and lonely, and espouse the stigma of others [9,10].
When patients internalize these public attitudes, self-
stigma occurs with numerous negative consequences.
Self-stigma is another major challenge for the patients
with SMI which includes not just being aware of the
public stigma but also accepting the stereotypes and
agreement with the prejudiced beliefs which in the
end results in negative emotional reactions (e.g. low
self-confidence) and behaviours in response to dis-
crimination (e.g. failing to continue school or job)
[11,12]. Studies revealed that self-stigma is related to
personal autonomy, quality of life, negative symptoms,
unemployment, recovery, self-esteem, self-efficacy, and
treatment adherence [13–19]. Since the stigmatization
is associated with one’s insight into the illness [20],
this phenomenon is essential concerning the thera-
peutic alliance and adherence to treatment.
Among the SMI, schizophrenia is one of the most
discriminated and stigmatized mental illnesses
[21,22]. Because of its chronic nature, compliance
and adherence to the treatment are crucial for the
patients with schizophrenia [23]. As an example,
researchers conducted a study investigating the factors
related to the medication compliance of the people
with schizophrenia and found a significant relationship
between self-stigmatization and medication compli-
ance. It was revealed that patients with high level of
self-stigma concerning the agreement with the stereo-
types of mental illness had poorer medication adher-
ence [24]. In that sense, assessing the self-stigma of
the patients with schizophrenia is essential regarding
illness prognosis and psychotherapy practices [25].
Self-stigma comprises several components such as:
stereotyping, labelling, discrimination, social withdra-
wal, and status loss [2]. In this regard, scales assessing
the self-stigma focus on one or more of those factors.
Some of the most widely used scales are the Interna-
lized Stigma of Mental Illness (ISMI) [26,27], Self-
Stigma of Mental Illness Scale (SSMIS) [28], Self-
Stigma Questionnaire (SSQ) [25], Perceived Devalua-
tion and Discrimination (PDD) Scale [8], Discrimi-
nation and Stigma Scale (DISC) [29], and Consumer
Experiences of Stigma Questionnaire (CESQ) [30].
These scales were originated from various countries;
thus, every stigma scale includes some cultural state-
ments along with universal concepts. Concerning the
stigma term, it was argued that stigmatization has
specific cultural aspects in which it should be evaluated
by considering the community and the culture it is ori-
ginated [31].
Since the stigmatization is a culture-specific
phenomenon [32,33], researchers from different
countries tried to develop a new scale or adapted the
existing scales into their culture. However, most of
the current scales were developed in Western-Euro-
pean cultural group and researchers from other cul-
tures mainly translated those commonly used scales
in their languages [34]. Relatively few studies focused
on the culture-specific aspect of stigmatization and
tried to construct a measurement that contains cultural
features of its society [35].
In Turkey, the most commonly used measure asses-
sing internalized stigma in mentally ill patients is a
translated scale originating from the Western culture
[27]. A culturally specific self-stigma scale developed
for this community is still lacking, to our best knowl-
edge. To be able to evaluate the self-stigma properly,
it is crucial for the patients to understand the questions
and that the items should reflect the stigma they experi-
enced in their cultural context. The purpose of this
study was to develop a culture-sensitive self-stigma
inventory for the patients with schizophrenia living
in Turkey and to measure its psychometric properties.
Methods
Participants
In this study, 162 outpatients diagnosed with schizo-
phrenia or schizoaffective disorder according to
DSM-5 criteria [36] were recruited from Kocaeli Uni-
versity School of Medicine Psychiatry Polyclinic
between September 2016 and July 2017. The partici-
pants of this study were the patients of the families par-
ticipated in our previous study of the “development of
Self-stigma Inventory for Families” that was approved
by the ethical committee for both the patients and
their relatives [37]. Ethical permission of the study
was taken from Kocaeli University Ethical Committee
of Non-invasive Clinical Research (KÜ GOKAEK
2016/61). Researchers gave information to the patients
about the study, and informed consent form was given
to those who agreed to participate.
Inclusion criteria
Participants were included to the study from those who
were 18–60 years of age, not having mental retardation
or any neurological disease that can affect their judg-
ment, at least primary school graduate, continuing to
their regular medical treatment, and not receiving
ECT in the last 6 months.
Instruments
Sociodemographic form
Patients were given a form developed by the research-
ers containing their sociodemographic information
such as gender, age, marital status, education,
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employment, the age of onset of the illness, duration of
the illness, and the number of hospitalizations.
The Global Assessment of Functioning (GAF) is
an instrument included in the axis V of DSM-IV-TR
mainly aims to assess the patients’ general functioning
on a scale range from 0 to 100. Higher scores indicate
better performance [38].
Positive and Negative Syndrome Scale (PANSS) is
a scale for rating the symptoms of the schizophrenia
(and other psychotic disorders). It assesses the symp-
toms of the patients as positive, negative, and general
psychopathology with its 7-point rating and 30-items
[39,40].
Clinical Global Impression-Severity (CGI-S) is a
clinical global assessment scale where the clinician rates
the severity of the illness following seven-point scale:
1 = normal, not at all ill; 2 = borderline mentally ill; 3 =
mildly ill; 4 =moderately ill; 5 =markedly ill; 6 = severely
ill; 7 = among the most extremely ill patients [41].
Internalized stigma of mental illness (ISMI) scale
The scale was developed by Ritsher et al. [26] and
adapted to Turkish culture by Ersoy and Varan [27].
It is a 4-point Likert type questionnaire with 29-item
assessing the self-stigma among the people with mental
illness. Cronbach’s alpha coefficient of the scale was
0.90 and 0.93 for original and Turkish versions,
respectively. It has 5 subscales defined as Alienation,
Stereotype Endorsement, Discrimination Experience,
Social Withdrawal, and Stigma Resistance. The total
score is calculated by grading the “strongly disagree”
as 1, “disagree” as 2, “agree” as 3, “strongly agree” as
4, and reverse the coding for the items in the last factor.
Minimum and maximum scores of the scale are
between 29 and 116. Higher scores indicate a higher
level of internalized stigmatization.
Beck Depression Inventory (BDI) was developed
by Beck et al. [42] to assess physical, emotional, and
cognitive symptoms observed in depression and the
study of its Turkish adaptation was conducted by
Hisli [43]. It is a 21-item self-assessment scale. Cron-
bach’s alpha coefficient was found as 0.90. Higher
scores indicate a higher level of depression.
Beck Hopelessness Scale (BHS) is a 20-item scale
developed by Beck, Lester, and Trexler [44], and
adapted to Turkish culture by Durak [45]. Internal
consistency of the scale was found as 0.86. Higher
scores from the scale indicate the higher level of
hopelessness.
Rosenberg self-esteem scale (RSES)
In this study, the 10-item Rosenberg Self-Esteem Scale
[46] was used. Turkish reliability and validity study of
the scale was conducted by Çuhadaroğlu [47]. Internal
consistency of the scale was 0.71. Higher scores indi-
cate higher self-esteem.
Self-stigma inventory for patients (SSI-P)
Existing stigma and self-stigma scales for people with
mental illnesses in both English and Turkish language
were examined, and items were evaluated. By taking
into consideration the Turkish culture and stereotypes
embedded in, a 19-item self-stigma questionnaire was
formed. Then, focus group interviews were conducted
with 20 patients with schizophrenia in which patients
talked about their opinions, thoughts, and beliefs
about the stigma in the society and the ones that they
accepted for themselves as a form of internalized
stigma. Collecting the information from patients them-
selves and integrating the statements of the patients
about their self-stigmatization into the scale, the
items were reviewed and rephrased into more compre-
hensible terms for the patients. The pilot study was
conducted with a sample of 15 people with schizo-
phrenia, and the inventory was finalized after reevalu-
ating the incoherent phrases. Answers to each item
were rated with a 5-point Likert scale: 1 = do not
agree, 2 = slightly agree, 3 = moderately agree, 4 = gen-
erally agree, 5 = totally agree. Higher scores indicate the
higher level of stigmatization.
Procedure
The SSI-P was given to the outpatients with schizo-
phrenia and schizoaffective disorder who gave
informed consent to the study together with a sociode-
mographic form, ISMI, BDI, RSES, and BHS. A psy-
chiatrist also evaluated the patients with the PANSS,
CGI-S, and GAF scales. To assess the test-retest
reliability, the SSI-P was given to a group of the selected
patients 2–3 weeks after the first administration.
Statistical analysis
Analyses were conducted with SPSS version 22.0. The
Kaiser–Meyer–Olkin (KMO) measure of sampling
adequacy and Bartlett’s tests of sphericity were carried
out to check preliminary assumptions, and the Princi-
pal Components Analysis and Direct Oblimin
Rotation were utilized for factor analysis. For internal
consistency, corrected item-total correlations, Cron-
bach’s alpha, and Cronbach’s alpha if item deleted
were calculated. For test-retest reliability and concur-
rent validity, Pearson or Spearman correlation was
used based on the distributional features of the
variables.
Results
One hundred and sixty-two outpatients with schizo-
phrenia and schizoaffective disorder participated and
completed the study. Majority of the patients were
males, single, and living with their parents. Sociodemo-
graphic information of the patients was given in Table 1.
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The validity of the SSI-P
Construct validity
Explanatory Factor Analysis (EFA) was conducted to
examine the construct validity. The KMO test indicated
excellent sampling adequacy (KMO= 0.920), and Bar-
tlett’s test of sphericity showed that a factor analysis
might be useful for the data (X2 = 1877.47, df = 171,
P < 0.001). In the EFA of the 19-item scale, 3 factors
were found which can explain 61.47% of the total var-
iance and has eigenvalue greater than 1. Factor analysis
was conducted with Direct Oblimin technique, and the
items with factor value less than 0.40 (item number 9,
12) were removed. Thereby, the scale had three factors
and 17 items. It was revealed that first factor explains
49.51%, the second factor explains 7.10%, and the last
factor explains 6.87% of the total variance, and;
together they explain 63.47% of the total variance. In
terms of the items constitutes the factors; first factor
(1, 2, 3, 4, 6, 7, 10, 11) was labelled as “perceived deva-
luation”, second factor (8, 14, 15, 16, 17, 18, 19)
described as “internalized stereotypes and social with-
drawal”, and third factor (5, 13) entitled as “conceal-
ment of the illness” (Table 2).
Content validity
Content validitywas assessedwith the correlation between
the total score of the scale and its subscales (Table 3).
A high correlation was found between the SSI-P total
score and perceived devaluation subscale (r = 0.92), inter-
nalized stereotypes and social withdrawal (r = 0.90), and
concealment of the illness subscale (r = 0.66).
Concurrent validity
Concurrent validity of the scale was calculated by its
correlation with the BDI, BHS, and RSES (Table 4).
The SSI-P and its subscales were significantly





Factor 2 internalized stereotypes
and social withdrawal
Factor 3 concealment of
the illness
6 I can’t take responsibilities like other people because of
my illness
0.923
4 I feel that I am useless because of my illness 0.868
10 I think that I am a burden to my family because of my
illness
0.839
2 I have lower self-confidence because of my illness 0.765
3 I think that people stay away from me because of my
illness
0.747
1 I think that people look at me like I’m mentally ill 0.667
7 I think that I can’t make proper decisions because of
my illness
0.607
11 Since I take medications, I feel like I am a drug addict 0.549
19 I think that I can’t be employed because of my illness 0.850
18 I think that nobody would marry me because of my
illness
0.800
17 I think that I can’t be a successful person because of my
illness
0.742
16 I think that I can’t be happy because of my illness 0.694
14 I stay away from people thinking that they wouldn’t
understand me
0.634
8 I stay away from people thinking that they make jokes
or comments that could hurt me
0.571
15 I think that people don’t care about me because of my
illness
0.565
5 I don’t tell my friends that I have a mental illness 0.867
13 I don’t say the real name of my illness to people around
me since I fear being excluded
0.592
Eigenvalues 8.416 1.206 1.168
Variance Explained, % 49.508 7.096 6.870
Total Variance Explained, % 63.47
Table 1. Sociodemographic characteristics of the patients
(schizophrenia = 135, schizoaffective disorder = 27).
Age (Mean ± SD) 35.57 ± 9.43 (19–64)
Education (Mean ± SD) 10.07 ± 3.38 (5–20)
Age of onset (Mean ± SD) 23.44 ± 7.19 (14–51)
Duration of illness/year (Mean ± SD) 14.12 ± 8.60 (1–41)
Number of hospitalizations (Mean ± SD) 2.57 ± 2.63 (0–16)
Gender / Male (n, %) 124 (76.5)
Marital status / Single (n, %) 113 (69.8)
Living with parents (n, %) 109 (67.3)
Unemployed or retired (n, %) 100 (61.7)









Perceived devaluation 0.921* 1.000
Internalized stereotypes and social withdrawal 0.902* 0.742* 1.000
Concealment of the illness 0.664* 0.483* 0.483* 1.000
*P < 0.01.
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correlated with all the scales; positively with BDI and
BHS, negatively with RSES.
Spearman correlation was carried out to assess the
correlation of the scale with clinical assessment tools.
The SSI-P was not significantly associated with
PANSS total, PANSS positive symptoms, PANSS gen-
eral psychopathology, GAF, and CGI-S scores (P >
0.05). The only correlation was found between
PANSS negative symptoms and SSI-P total scores (P
< 0.05), yet the magnitude of the association was
quite low (r = 0.20).
The other scale used as convergent validity was
ISMI. Table 5 shows the correlations between the
ISMI and SSI-P total scores and subscales. A high posi-
tive correlation was found between ISMI and SSI-P
total scores. The correlations between the subscales
were also quite high except the “concealment of the ill-
ness” factor from the SSI-P and “stigma resistance”
subscale from the ISMI.
Reliability of SSI-P
Internal consistency reliability
In the internal consistency analysis, Cronbach’s alpha
internal consistency coefficient of the scale was calcu-
lated as 0.932 for the SSI-P with 17 items. Cronbach’s
alpha coefficient of perceived devaluation factor was
0.91, internalized stereotypes and social withdrawal fac-
tor was 0.87, and concealment of the illness was 0.60.
Data concerning the item-total correlations and Cron-
bach’s Alpha coefficients calculated for each item
through if item deleted technique (Table 6). Item-total
score correlation coefficients were between 0.31 and
0.76, and all were statistically significant (P < 0.001).
Test-retest reliability
For the test-retest reliability analysis, the SSI-P was
given to 30 patients in 2–3 weeks after the first










SSI-P total 0.531** 0.402** −0.585** 0.139 0.046 0.199* 0.146 0.137 −0.094
Perceived devaluation 0.554** 0.341** −0.626** 0.160* 0.072 0.202** 0.158* 0.120 −0.113
Internalized stereotypes & social
withdrawal
0.507** 0.447** −0.564** 0.109 0.039 0.162* 0.115 0.124 −0.091
Concealment of the illness 0.235** 0.210** −0.163* 0.117 0.006 0.176* 0.129 0.088 −0.014
*P < 0.05.
**P < 0.01.










SSI-P 0.728** 0.704** 0.521** 0.610** 0.693** 0.202*
Perceived devaluation 0.735** 0.702** 0.514** 0.639** 0.669** 0.221**
Internalized stereotypes & social
withdrawal
0.636** 0.631** 0.443** 0.517** 0.635** 0.186*
Concealment of the illness 0.367** 0.377** 0.278** 0.270** 0.353** 0.093
*P < 0.05.
**P < 0.01.







1 I think that people look at me like I’m mentally ill 0.655 0.935
2 I have lower self-confidence because of my illness 0.760 0.933
3 I think that people stay away from me because of my illness 0.747 0.933
4 I feel that I am useless because of my illness 0.738 0.933
5 I don’t tell my friends that I have a mental illness 0.307 0.942
6 I can’t take responsibilities like other people because of my illness 0.682 0.934
7 I think that I can’t make proper decisions because of my illness 0.638 0.935
8 I stay away from people thinking that they make jokes or comments that could hurt me 0.610 0.936
9 I think that people are afraid that I could lose control because of my illness 0.646 0.935
10 I think that I am a burden to my family because of my illness 0.717 0.934
11 Since I take medications, I feel like I am a drug addict 0.588 0.936
12 I think that other people would be afraid of me when they hear that I am receiving
psychiatric treatment
0.638 0.935
13 I don’t say the real name of my illness to people around me since I fear being excluded 0.556 0.937
14 I stay away from people thinking that they wouldn’t understand me 0.730 0.933
15 I think that people don’t care about me because of my illness 0.706 0.934
16 I think that I can’t be happy because of my illness 0.693 0.934
17 I think that I can’t be a successful person because of my illness 0.750 0.933
18 I think that nobody would marry me because of my illness 0.591 0.936
19 I think that I can’t be employed because of my illness 0.597 0.936
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administration. The results were analyzed through the
Spearman correlation test. The test-retest reliability
coefficient of the scale was r = 0.829 (P < 0.01).
Association between the SSI-P and
sociodemographic variables
The mean SSI-P scores for the patients with schizo-
phrenia and schizoaffective disorder were calculated
as 37.6 (SD = 16.58), and 39.1 (SD = 20.40), respect-
ively, and the average total scores did not differ statisti-
cally according to the diagnostic groups (P = 0.68).
Moreover, the mean SSI-P total scores were not statisti-
cally different for gender (M = 38.72 ± 17.66, F = 35.21
± 15.59, P = 0.27), the living condition (with parents =
37.87 ± 16.59, family = 37.03 ± 17.59, relatives = 35.80
± 26.30, alone = 40.35 ± 19.82, P = 0.96), marital status
(married = 36.19 ± 18.68, single = 38.09 ± 16.16, separ-
ated/divorced = 41.33 ± 2.69, P = 0.65), employment
status (retired = 45.21 ± 21.06, employed = 38.71 ±
19.26, unemployed = 35.86± 15.04, P = 0.06), and the
level of family support (low = 43.25 ± 19.28, high =
36.87 ± 16.60, P = 0.09). Furthermore, SSI-P was not
significantly correlated with the age (P = 0.58), level
of education (P = 0.44), the onset of the illness (P =
0.10), duration of the illness (P = 0.29), and the number
of hospitalizations (P = 0.79).
Discussion
The results of the study showed that the SSI-P is a
reliable and valid instrument for assessing the self-stig-
matization of people with schizophrenia and schi-
zoaffective disorder. The Cronbach’s alpha
correlation coefficient value of the scale was 0.93 indi-
cating high reliability. The factor analysis revealed that
the scale has excellent construct validity with its 3 fac-
tors called perceived devaluation, internalized stereo-
types and social withdrawal, and concealment of the
illness. The SSI-P total score was highly correlated
with its factors indicating the content validity of the
scale.
Concerning the convergent validity, the SSI-P was
significantly correlated with the BDI, BHS, RSES, and
ISMI. The relationship of self-stigma with depression,
hopelessness, and self-esteem was also revealed in pre-
vious studies [28,48–50] which supports our results of
the moderate correlation. These studies found that self-
stigma is positively correlated with depression, hope-
lessness, and negatively correlated with self-esteem.
Some studies also found a relationship between the
severity of the illness (CGI-S) and self-stigma [51].
However, we did not find a significant correlation
between SSI-P and CGI-S in this study. The reason
might be the difference between SSI-P and other scales
concerning the content and context of the stigma
items; also, the cultural differences might affect the
relationship between the severity of the illness and
self-stigmatization of the patients. Additionally, while
some researchers found that both positive and negative
symptoms of schizophrenia were associated with self-
stigma [52]; others found that only negative symptoms
directly affected the hopelessness, depression, and self-
stigma [48]. Our study supported the latter research by
revealing a positive correlation only between PANSS
negative symptoms and SSI-P total score. Although it
was a small correlation, it is noteworthy that the corre-
lations differ according to different kind of stigma
scales. Furthermore, we could not find any association
between GAF and SSI-P. In SSQ study, they found a
small correlation between GAF and SSQ at a p-value
of 0.047 (r = 0.23), which is very close to non-signifi-
cance level. In that sense, it can be concluded that gen-
eral functioning is not strongly associated with the level
of self-stigmatization of the patients. Apart from that,
SSI-P did not statistically change according to the
sociodemographic information of the patients such as
gender, marital status, employment, etc.
In Turkey, the most commonly used scale for self-
stigma is the ISMI, and our new scale was strongly
correlated with this scale (r = 0.73, P < 0.01). It was
revealed that both ISMI and SSI-P have Cronbach’s
alpha value of 0.93; meaning the new scale is as
reliable as the commonly used one. The advantage
of the SSI-P is that it has high internal consistency
with much fewer items compared to ISMI. Addition-
ally, the SSI-P was constructed together with the
patients by considering of their beliefs and thoughts;
thus, the items are more comprehensible for the
patients, and it is the first culturally sensitive scale
that was developed for this culture. In our country,
existing stigma scales were all translated versions of
Western-origin scales. Therefore, this new scale is
imperative in terms of containing culture-specific
items and being sensitive to collectivistic social virtues
[53]. Since the scale has only 17 items and no reversed
items, its calculation is also quite easy. One of the
most significant advantages of the SSI-P is its
reader-friendly and easy-to-comprehend structure;
because we included the statements directly from
the patients themselves to the scale as items. One
difference between the ISMI and SSI-P was that in
SSI-P there were no items related to the Stigma Resist-
ance factor in ISMI. We did not include any statement
from this specific factor since that kind of topic was
never brought up by the patients during the meetings
or interviews we conducted about their self-stigmati-
zation. We concluded that statements related to
stigma resistance need not be included in the scale
since our patients did not have the concept of “resist-
ance” when they think about the self-stigma. That was
the reason that every factor of the SSI-P and ISMI
were moderate to strongly correlated with each
other except the Stigma Resistance factor of ISMI.
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The explanatory factor analysis revealed that the
SSI-P has three factors, and the factors could explain
63.5% of the total variance. The first factor comprised
of the items related to the patients’ thought of inability
to take responsibilities, feelings of uselessness, feeling
like a burden to their family, having low self-confi-
dence, thoughts about people avoiding them, thinking
that others see them as “sick”, thinking that they can-
not take proper decisions on their own, and the feeling
of a drug addict. These items were categorized as per-
ceived devaluation. Although some of the items were
placed in “social discrimination” and “perceived capa-
bilities” factors in another scale [24]; they gathered into
one factor in our study. We concluded that those nega-
tive feelings and attitudes of the patients were derived
from the perception of devaluation they had.
In the second factor, items about patients’ unem-
ployment, thought of being unable to get married,
social withdrawal from their environment, and
thoughts of others not caring them clustered into
same factor merging with the items including the feel-
ings of being unsuccessful and unhappy. This factor
was labelled as internalized stereotypes and social with-
drawal. The fact that stereotypical thoughts could not
be differentiated as a separate factor might be the result
of that the failure and unhappiness are closely associ-
ated with social withdrawal in our culture. It was inter-
preted that stereotype endorsement and internalization
also lead to withdrawal from the society as well for the
patients with schizophrenia in Turkey. In the third fac-
tor, hiding the name of the illness from their close cir-
cle, environment, and their friends are defined as
concealment of the illness. These items were also
included in other self-stigma scales as in the same fac-
tor [25]. Moreover, in our previous study, we similarly
found three factors (social withdrawal, concealment of
the illness, and perceived devaluation) that could
explain 66.8% of the total variance of the Self-Stigma
Inventory for Families (SSI-F) [37].
Limitations of the study
This study has some limitations. Firstly, the study was
conducted in a single-centre facility and with the
patients who are compliant with their medical treat-
ment. Thus, it may have affected its external validity,
and the study might not be generalized for those
unstable and non-adherent patients. Secondly, the
study was carried out only with the people with schizo-
phrenia and schizoaffective disorder. Its reliability and
validity should also be investigated for other psychotic
disorders and severe mental illnesses in general.
Thirdly, we used the ISMI to evaluate the convergent
validity of the scale; however, it would be better if the
scale was compared with another reliable, valid, and
culture-sensitive instrument developed in the same cul-
ture. Nonetheless, since this was the first self-stigma
scale developed for this culture, we had to use a trans-
lated stigma scale.
Despite the limitations, the SSI-P was the first cul-
ture-sensitive, a user-friendly scale that was aimed to
assess the self-stigmatization of the patients with
schizophrenia and schizoaffective disorder living in
Turkey. We believe that this scale can also be adapted
to different cultures and languages since it includes the
essence of the stigma concept and comprehensible to
the patients’ self-evaluations. Furthermore, future
studies should be done to replicate the results and
further validate the inventory. Although this study
stands for the preliminary results of the new scale, it
can be said that it is a useful and practical tool in asses-
sing self-stigmatization of the patients with schizo-
phrenia regarding clinical practices and therapeutic
purposes.
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Appendices
Appendix A. Self-stigma inventory for patients with schizophrenia (SSI-P) in Turkish
ŞİZOFRENİ HASTALARINDA KENDİNİ DAMGALAMA ÖLÇEĞİ (KDÖ-H).
Adı soyadı:… … … … … … … … … … … … … Tarih:… … /… . /… … …
Appendix B. Self-stigma inventory for patients with schizophrenia (SSI-P) in English
SELF-STIGMA INVENTORY FOR PATIENTS WITH SCHIZOPHRENIA (SSI-P).
Name:… … … … … … … … … … … … … Date:… … /… . /… … …
Aşağıda ruhsal hastalığı olan kişilerin genellikle yaşadığı sıkıntılar listelenmiştir.
Yaşadığınız sıkıntıların şiddetini anlayabilmemiz için her maddede kendinize en











1 İnsanların bana akıl hastasıymışım gibi baktıklarını düşünüyorum
2 Hastalığımdan dolayı kendime olan güvenim azaldı
3 Hastalığımdan dolayı insanların benden uzaklaştığını düşünüyorum
4 Hastalığımdan dolayı kendimi işe yaramaz hissediyorum
5 Hastalığımdan dolayı aileme yük olduğumu düşünüyorum
6 Hastalığımdan dolayı sorumluluklarımı diğer insanlar gibi yerine
getiremiyorum
7 Hastalığımdan dolayı uygun kararlar alamayacağımı düşünüyorum
8 İlaç kullandığım için kendimi ilaç bağımlısı gibi hissediyorum
9 Hastalığımla ilgili olarak beni incitecek yorum ya da şaka yaparlar diye
insanlardan uzak duruyorum
10 Beni anlamayacaklarını düşündüğüm için çevremdeki insanlardan uzak
duruyorum
11 Hastalığımdan dolayı çevremdeki insanların beni önemsemediklerini
düşünüyorum
12 Hastalığımdan dolayı mutlu olamayacağımı düşünüyorum
13 Hastalığımdan dolayı başarılı olamayacağımı düşünüyorum
14 Hastalığımdan dolayı benimle kimsenin evlenmeyeceğini düşünüyorum
15 Hastalığımdan dolayı işe alınmayacağımı düşünüyorum
16 Arkadaşlarıma ruhsal bir hastalığım olduğunu söylemiyorum
17 Dışlanmaktan korktuğum için çevremdeki insanlara hastalığımın gerçek
adını söylemiyorum
The most common problems experienced by the people with mental illness
are listed below. Please put a mark on the option that best suits you in each











1 I think that people look at me like I’m mentally ill
2 I have lower self-confidence because of my illness
3 I think that people stay away from me because of my illness
4 I feel that I am useless because of my illness
5 I think that I am a burden to my family because of my illness
6 I can’t take responsibilities like other people because of my illness
7 I think that I can’t make proper decisions because of my illness
8 Since I take medications, I feel like I am a drug addict
9 I stay away from people thinking that they make jokes or comments
that could hurt me
10 I stay away from people thinking that they wouldn’t understand me
11 I think that people don’t care about me because of my illness
12 I think that I can’t be happy because of my illness
13 I think that I can’t be a successful person because of my illness
14 I think that nobody would marry me because of my illness
15 I think that I can’t be employed because of my illness
16 I don’t tell my friends that I have a mental illness
17 I don’t say the real name of my illness to people around me since I fear
being excluded
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